1.    PRODUCT OVERVIEW

1.1.  MARKET DEFINITION

1.2.  SCOPE OF THE MARKET

1.2.1.    MARKETS COVERED

1.2.2.    YEARS CONSIDERED FOR STUDY

1.2.3.    KEY MARKET SEGMENTATIONS

2.    RESEARCH METHODOLOGY

2.1.  OBJECTIVE OF THE STUDY

2.2.  BASELINE METHODOLOGY

2.3.  KEY INDUSTRY PARTNERS

2.4.  MAJOR ASSOCIATION AND SECONDARY SOURCES

2.5.  FORECASTING METHODOLOGY

2.6.  DATA TRIANGULATION & VALIDATION

2.7.  ASSUMPTIONS AND LIMITATIONS

3.    EXECUTIVE SUMMARY

3.1.  OVERVIEW OF THE MARKET

3.2.  OVERVIEW OF KEY MARKET SEGMENTATIONS

3.3.  OVERVIEW OF KEY MARKET PLAYERS

3.4.  OVERVIEW OF KEY REGIONS/COUNTRIES

3.5.  OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS

4.    VOICE OF CUSTOMER

5.     JAPAN PROSTATE CANCER DRUGS MARKET OUTLOOK

5.1.  MARKET SIZE & FORECAST

5.1.1.    BY VALUE

5.2.  MARKET SHARE & FORECAST

5.2.1.    BY DRUG CLASS (HORMONAL THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, TARGETED THERAPY)

5.2.2.    BY END USER (CLINICS, HOSPITAL, OTHERS)

5.2.3.    BY DISTRIBUTION CHANNEL (HOSPITAL PHARMACIES, RETAIL PHARMACIES, ONLINE SALES, OTHERS)

5.2.4.    BY REGION

5.2.5.    BY COMPANY (2024)

5.3.  MARKET MAP

6.    HOKKAIDO PROSTATE CANCER DRUGS MARKET OUTLOOK

6.1.  MARKET SIZE & FORECAST

6.1.1.    BY VALUE

6.2.  MARKET SHARE & FORECAST

6.2.1.    BY DRUG CLASS

6.2.2.    BY DISTRIBUTION CHANNEL

6.2.3.    BY END USER

7.    TOHOKU PROSTATE CANCER DRUGS MARKET OUTLOOK

7.1.  MARKET SIZE & FORECAST

7.1.1.    BY VALUE

7.2.  MARKET SHARE & FORECAST

7.2.1.    BY DRUG CLASS

7.2.2.    BY DISTRIBUTION CHANNEL

7.2.3.    BY END USER

8.    KANTO PROSTATE CANCER DRUGS MARKET OUTLOOK

8.1.  MARKET SIZE & FORECAST

8.1.1.    BY VALUE

8.2.  MARKET SHARE & FORECAST

8.2.1.    BY DRUG CLASS

8.2.2.    BY DISTRIBUTION CHANNEL

8.2.3.    BY END USER

9.    CHUBU PROSTATE CANCER DRUGS MARKET OUTLOOK

9.1.  MARKET SIZE & FORECAST

9.1.1.    BY VALUE

9.2.  MARKET SHARE & FORECAST

9.2.1.    BY DRUG CLASS

9.2.2.    BY DISTRIBUTION CHANNEL

9.2.3.    BY END USER

10. KANSAI PROSTATE CANCER DRUGS MARKET OUTLOOK

10.1.   MARKET SIZE & FORECAST        

10.1.1. BY VALUE

10.2.   MARKET SHARE & FORECAST

10.2.1. BY DRUG CLASS

10.2.2. BY DISTRIBUTION CHANNEL

10.2.3. BY END USER

11. CHUGOKU PROSTATE CANCER DRUGS MARKET OUTLOOK

11.1.   MARKET SIZE & FORECAST        

11.1.1. BY VALUE

11.2.   MARKET SHARE & FORECAST

11.2.1. BY DRUG CLASS

11.2.2. BY DISTRIBUTION CHANNEL

11.2.3. BY END USER

12. SHIKOKU PROSTATE CANCER DRUGS MARKET OUTLOOK

12.1.   MARKET SIZE & FORECAST        

12.1.1. BY VALUE

12.2.   MARKET SHARE & FORECAST

12.2.1. BY DRUG CLASS

12.2.2. BY DISTRIBUTION CHANNEL

12.2.3. BY END USER

13. KYUSHU PROSTATE CANCER DRUGS MARKET OUTLOOK

13.1.   MARKET SIZE & FORECAST        

13.1.1. BY VALUE

13.2.   MARKET SHARE & FORECAST

13.2.1. BY DRUG CLASS

13.2.2. BY DISTRIBUTION CHANNEL

13.2.3. BY END USER

14. MARKET DYNAMICS

14.1.   DRIVERS

14.2.   CHALLENGES

15. MARKET TRENDS & DEVELOPMENTS

15.1.   RECENT DEVELOPMENTS

15.2.   PRODUCT LAUNCHES

15.3.   MERGERS & ACQUISITIONS

16.  JAPAN PROSTATE CANCER DRUGS MARKET: SWOT ANALYSIS

17. COMPETITIVE LANDSCAPE

17.1.   JOHNSON & JOHNSON KK

17.1.1.       BUSINESS OVERVIEW

17.1.2.       PRODUCT & SERVICE OFFERINGS

17.1.3.       RECENT DEVELOPMENTS

17.1.4.       KEY PERSONNEL

17.1.5.       FINANCIALS (IF LISTED)

17.1.6.       SWOT ANALYSIS

17.2.   ASTELLAS PHARMA INC

17.3.   IPSEN PHARMA

17.4.   SANOFI

17.5.   BAYER AG

17.6.   ABBVIE INC

17.7.   ASTRAZENECA

17.8.   PFIZER INC

17.9.   ABBOTT LABORATORIES INC.

17.10.GSK PLC

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIMER